

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN

ZOTAROLIMUS

PRONUNCIATION

zoe ta roe' li mus


THERAPEUTIC CLAIM

Drug component of phosphorycholine polymer coated drug-eluting stent currently under evaluation for the prevention of coronary restenosis following stent replacement

CHEMICAL NAMES

1. Rapamycin, 42-deoxy-42-(1*H*-tetrazol-1-yl)-, (4*2S*)-
2. (1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*E*,30*S*,32*S*,35*R*)-1,18-dihydroxy-19,30-dimethoxy-12-[(1*R*)-2-[(1*S*,3*R*,4*S*)-3-methoxy-4-(1*H*-tetrazol-1-yl)cyclohexyl]-1-methylethyl]-15,17,21,23,29,35-hexamethyl-11,36-dioxo-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

STRUCTURAL FORMULA



Nomenclature Statement

ZOTAROLIMUS

Page 2

MOLECULAR FORMULA

$C_{52}H_{79}N_5O_{12}$

MOLECULAR WEIGHT

966.2

TRADEMARK

Unknown as yet

MANUFACTURER

Abbott Laboratories

CODE DESIGNATION

ABT-578

CAS REGISTRY NUMBER

221877-54-9